PT - JOURNAL ARTICLE AU - Klaassen, Fayette AU - Swartwood, Nicole A AU - Chitwood, Melanie H AU - Lopes, Rafael AU - Haraguchi, Masahiko AU - Salomon, Joshua A AU - Cohen, Ted AU - Menzies, Nicolas A TI - National- and state-level SARS-CoV-2 immunity trends from January 2020 to December 2023: a mathematical modeling analysis AID - 10.1101/2024.10.22.24315935 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.22.24315935 4099 - http://medrxiv.org/content/early/2024/10/23/2024.10.22.24315935.short 4100 - http://medrxiv.org/content/early/2024/10/23/2024.10.22.24315935.full AB - Introduction Effective immune protection against SARS-CoV-2 infection and severe COVID-19 disease continues to change due to viral evolution and waning immunity. We estimated population-level immunity to SARS-CoV-2 for each of the fifty United States (U.S.) and the District of Columbia from January 2020 through December 2023.Methods We updated a model of SARS-CoV-2 infections to align with the latest evidence on SARS-CoV-2 natural history and waning of immunity, and to integrate various data sources available throughout the pandemic. We used this model to produce population estimates of effective protection against SARS-CoV-2 infection and severe COVID-19 disease.Results On December 30, 2023, 99.9% of the U.S. population had experienced immunological exposure to SARS-CoV-2 through infection and/or vaccination, with 99.4% (95% credible interval (CrI): 92.4-100%) having had at least one SARS-CoV-2 infection. Despite this high exposure, the average population-level protection against infection was 53.6% (95% CrI: 38.7-71.5%). Population-level protection against severe disease was 82.6% (95% CrI: 71.5-91.7%).Discussion A new wave of SARS-CoV-2 infections and COVID-19-associated hospitalizations began near the end of 2023, with the introduction of the JN.1 variant. This upturn suggests that the U.S. population remains at risk of SARS-CoV-2 infection and severe COVID-19 disease despite the high level of cumulative exposure in the United States. This decline in effective protection is likely due to both waning and continued viral evolution.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has been funded (in part) by contract number 200-2016-91779 with the Centers for Disease Control and Prevention (CDC) and funding from the Centers for Disease Control and Prevention through the Council of State and Territorial Epidemiologists (Grant Number NU3OT000297).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll code and data used in this analysis are available on GitHub (https://github.com/covidestim). The produced datasets are available on the Harvard Dataverse (https://doi.org/10.7910/DVN/G2ZXJG).